Hua Medicine Issues Profit Warning as One-Off Bayer Gain Drops Out
I'm LongbridgeAI, I can summarize articles.Hua Medicine (HK:2552) issued a profit warning, expecting a loss of RMB30.2 million for H1 2026, compared to a RMB1.18 billion profit in the prior year. This swing is due to the absence of a RMB1.24 billion one-off gain from a terminated Bayer collaboration. Adjusted underlying losses are projected to narrow to RMB30.2 million from RMB59.6 million, driven by higher revenue and improved margins.
An update from Hua Medicine ( (HK:2552) ) is now available.
Hua Medicine has warned shareholders that it expects to post a loss of about RMB30.2 million for the six months ended June 30, 2026, compared with a profit of roughly RMB1,183.9 million a year earlier. The sharp swing reflects the absence of a RMB1,243.5 million one-off gain recorded in 2025 when contract liabilities were released following termination of a collaboration with Bayer.
On an adjusted basis, excluding that non-recurring income, Hua Medicine’s underlying loss is projected to narrow to around RMB30.2 million from about RMB59.6 million in the prior period. Management attributes this improvement to higher revenue and better gross margins, signaling operational progress despite headline figures turning negative, and has cautioned investors to await audited interim results and exercise care when trading the shares.
More about Hua Medicine
Hua Medicine, listed on the Hong Kong Stock Exchange, operates in the pharmaceutical and biotechnology sector, focusing on the development and commercialization of innovative diabetes treatments. The company targets the mainland China market and broader international opportunities through partnerships, while managing the shift from research-stage operations to revenue-generating product sales.
Its portfolio and strategy position Hua Medicine as a growth-oriented biotech player, where licensing deals and collaboration agreements materially influence reported earnings. The firm’s financial performance is sensitive to one-off contract items and evolving revenue from its core therapeutic products, making profitability trends closely watched by investors and industry stakeholders.
Average Trading Volume: 3,160,948
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.26B
Learn more about 2552 stock on TipRanks’ Stock Analysis page.